At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Choline alphoscerate +1 moredrug
Likely dose
Choline alphoscerate 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment
In Brief
A Phase 2 clinical trial evaluating Choline alphoscerate and Placebo for Vascular Cognitive Impairment. Completed, enrolled 62 participants across 1 site.
Detailed Summary
The purpose of this study is to assess whether the combination of choline alphoscerate 1200mg per day and nimodipine 90mg per day given orally is more effective than the combination nimodipine placebo in reducing cognitive decline in patients with subcortical vascular cognitive impairment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVascular Cognitive Impairment
CountriesItaly
CollaboratorsMDM S.p.A.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedJul 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedJul 25, 2017
Enrollment StartMay 2, 2017
Primary CompletionJul 9, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.9 years ago
Interventions
Choline alphosceratedrug
Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
Placebodrug
Placebo b.i.d plus Nimodipine 30 mg t.i.d